Search

Displaying results 2931 - 2940 of 4600 in total
  1. Drug

    Human interferon omega-1

    go.drugbank.com/drugs/DB05472
    Investigational

    It occurs naturally in the human body and is currently being manufactured by Intarcia through genetic engineering.

  2. Drug

    Urea C-13

    go.drugbank.com/drugs/DB09510
    ApprovedInvestigational

    To detect H. pylori, urea labeled with 13C is swallowed by the patient.

  3. Drug

    XEN-D0101

    go.drugbank.com/drugs/DB06020
    Experimental

    XEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.

  4. Drug

    Delamanid

    go.drugbank.com/drugs/DB11637
    ApprovedInvestigational

    Delamanid is approved by the EMA and is marketed under the trade name Deltyba as oral tablets. It is marketed by Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan).

  5. Drug

    Butorphanol

    go.drugbank.com/drugs/DB00611
    ApprovedIllicitVet approved

    A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.

  6. Drug

    Tubercidin

    go.drugbank.com/drugs/DB03172
    Experimental

    An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids

  7. Drug

    Talc

    go.drugbank.com/drugs/DB09511
    ApprovedInvestigational

    In fact, recent studies have reported that talc increases the risk of ovarian and endometrial cancers by approximately 30 percent.

  8. Drug

    Vayarin

    go.drugbank.com/drugs/DB09328
    Approved

    Vayarin is currently available only by prescription in the USA [L1502]. This drug has also been used for management of hypertriglyceridemia [L1503].

  9. Drug

    Vicriviroc

    go.drugbank.com/drugs/DB06652
    Investigational

    This drug was developed by Schering-Plough.

  10. Drug

    Ulotaront

    go.drugbank.com/drugs/DB15665
    Investigational

    [A193506] SEP-363856 was developed by Sunovion pharmaceuticals. … Unlike other drugs used for this condition, SEP-363856 does not bind to the dopamine D2 receptors, but exerts actions on the trace amine–associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5